Nithya Ramnath
Marylou Kennedy Research Professor of Thoracic Oncology
Professor of Internal Medicine
[email protected]

Available to mentor
Nithya Ramnath
Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Global REACH
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.
      Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Sci Rep, 2024 Jan 3; 14 (1): 345 DOI:10.1038/s41598-023-48546-y
      PMID: 38172168
    • Journal Article
      Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer.
      Edwards DM, Pirzadeh M, Van T, Jiang R, Tate A, Schaefer G, James J, Bishop C, Wilson C, Nedzesky N, Alseri A, Leveque A, Malus A, Waljee A, Elliott DA, Deng J, Schwartz A, Schipper M, Bryant AK, Ramnath N, Green MD. Cancer, 2024 Sep 1; 130 (17): 2910 - 2917. DOI:10.1002/cncr.35340
      PMID: 38853532
    • Journal Article
      Phase II Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients with Locally Advanced Non-Small Cell Lung Cancer.
      Edwards DM, Schonewolf CA, Rice JD, Schipper M, Haken RKT, Matuszak M, Balter J, Jarema D, Arenberg DA, Piert M, Qin A, Kalemkerian GP, Schneider BJ, Ramnath N, Chapman CH, Elliott DA, Lawrence TS, Hearn J, Hayman JA, Jolly S. Int J Radiat Oncol Biol Phys, 2024 Jul 4; DOI:10.1016/j.ijrobp.2024.06.018
      PMID: 38971385
    • Journal Article
      Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer.
      Moeller J, Green MD, Ramnath N. Transl Lung Cancer Res, 2024 Jun 30; 13 (6): 1444 - 1449. DOI:10.21037/tlcr-24-111
      PMID: 38973952
    • Journal Article
      Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances.
      Bryant AK, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles KM, Rae JM, Tate A, Pearson AN, Jiang R, Fritsche L, Lawrence TS, Zou W, Schipper M, Ramnath N, Yoo S, Crivelli S, Green MD. Cancer Med, 2024 Jun; 13 (12): e7253 DOI:10.1002/cam4.7253
      PMID: 38899720
    • Journal Article
      Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.
      Bryant AK, Lewy JR, Bressler RD, Chopra Z, Gyori DJ, Bazzell BG, Moeller JA, Jacobson SI, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Vaishnav P, Strohbehn GW. Lancet Oncol, 2024 Jun; 25 (6): 802 - 810. DOI:10.1016/S1470-2045(24)00200-6
      PMID: 38821085
    • Journal Article
      Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC.
      Zhou KI, Lin C, Tseng C-L, Ramnath N, Dowell JE, Kelley MJ. JTO Clin Res Rep, 2024 May; 5 (5): 100670 DOI:10.1016/j.jtocrr.2024.100670
      PMID: 38746048
    • Journal Article
      Abstract 2589: Novel workflow to generate natural killer cell sensitivity prediction model based on the epithelial mesenchymal transition related reprogramming at a single cell resolution
      Zou Y, Ball H, Harris C, Ramnath N, Keshamouni V, Nagrath S. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 2589 - 2589. DOI:10.1158/1538-7445.am2024-2589